APA (7th ed.) Citation

SC, M., HB, Z., J, W., YP, Z., XJ, G., LL, L., . . . X, B. (2021). De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma. Frontiers in oncology, 11, 666145. https://doi.org/10.3389/fonc.2021.666145

Chicago Style (17th ed.) Citation

SC, Ma, et al. "De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma." Frontiers in Oncology 11 (2021): 666145. https://doi.org/10.3389/fonc.2021.666145.

MLA (9th ed.) Citation

SC, Ma, et al. "De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma." Frontiers in Oncology, vol. 11, 2021, p. 666145, https://doi.org/10.3389/fonc.2021.666145.